
Wednesday, June 11, 2025 11:17:47 AM
1) Dr. Kaufmann is now a FT consultant (explains why he is not on the Management list).
2) He was at the Rett meeting to discuss with the Rett folks the next Rett trial.
3) Anavex's complete attention is focused on getting Blarcamesine approved by EMA.
4) TGD thought a virtual ASM would allow for more people to watch and experience it. It is possible a combination (in-person and virtual) might occur in the future.
5) Clint has not been told to list the ASM video on the web site.
6) In response to my comment of "I am waiting for rocket time," he quickly added "Buckle up."
It was a good call from my standpoint of what I was interested in speaking to Clint (I was expecting a voice mail and was very glad he answered).
For those who moved, thankfully, on Hoskuld's suggestion about Verona (VRNA) last summer, we are getting a very nice 🚀 time now. I think Anavex will be a BIG 🚀 by this time next year.
ANAVEX NOW!!!

Recent AVXL News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/14/2025 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
- Anavex Life Sciences to Participate at Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/14/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:31:17 PM
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:30:00 AM
- Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 05/01/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2025 12:00:38 AM
- Anavex Life Sciences to Participate in The Citizens Life Sciences Conference • GlobeNewswire Inc. • 04/30/2025 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/25/2025 08:40:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/25/2025 08:35:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/25/2025 08:31:01 PM
- Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board • GlobeNewswire Inc. • 04/23/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East • GlobeNewswire Inc. • 04/21/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/05/2025 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:45:40 AM
- Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2025 11:30:00 AM
- Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/24/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2025 02:06:26 PM
- Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/12/2025 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 • GlobeNewswire Inc. • 02/05/2025 12:30:00 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM